Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802155 | 0.89 | L3MBTL1 (0.56) | FFAR1AKR1C3AKR1C2AKR1C1L3MBTL1 | |
| SCHEMBL6645336 | 0.82 | AKR1C3 (0.49) | AKR1C3AKR1C2AKR1C1L3MBTL1PTGS1 | |
| SCHEMBL6050076 | 0.78 | MTNR1A (0.49) | CYP1A2AKR1C3AKR1C2AKR1C1L3MBTL1 | |
| SCHEMBL10202967 | 0.78 | MTNR1A (0.54) | CYP1A2MTNR1AMTNR1BCTBP2MEN1 | |
| SCHEMBL7041441 | 0.78 | MTNR1A (0.61) | AKR1C3AKR1C2AKR1C1L3MBTL1PTGS1 | |
| SCHEMBL31483406 | 0.76 | PTGS1 (0.51) | FFAR1L3MBTL1PTGS1CTSAMEN1 | |
| SCHEMBL10717750 | 0.76 | MEN1 (0.54) | CYP1A2L3MBTL1MEN1KMT2A | |
| SCHEMBL6366469 | 0.76 | GLS (0.54) | AKR1C3AKR1C2AKR1C1L3MBTL1PTGS1 | |
| SCHEMBL6366464 | 0.76 | GLS (0.54) | AKR1C3AKR1C2AKR1C1L3MBTL1PTGS1 | |
| SCHEMBL2020322 | 0.76 | AKR1C3 (0.70) | AKR1C3AKR1C2AKR1C1L3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146874-B1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| EP-0977735-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6495560-B1 | 10,11-DIHYDRO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)-1 -ETHOXY)-5H-DIBENZO(A,D)CYCLOHEPTENE-10-ACETIC ACID; TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-1146874-A4 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORP (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1146874-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SmithKline Beecham Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6191304-B1 | REDUCTION OF AN ALKYL 3-ALKYLOXY-11-OXO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-10-ACETATE BY HYDROGENOLYSIS USING A PALLADIUM/ACTIVATED CARBON CATALYST; INTERMEDIATES FOR3-((4-AMINOPYRID-2-YL)AMINOALKYLENEOXY) DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-02-20 | — | — | US | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000033838-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-6069158-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0977735-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0977735-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998030542-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | FFAR1 200/4885CYP1A2 3273/4885AKR1C3 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.